Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics Dose Escalation of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

NCT00722293 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00722293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00722293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics Dose Escalation of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
July 8, 2008
Completion date
February 25, 2014
Enrollment
111 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast